Short answer: Semaglutide activates one receptor (GLP-1). Retatrutide activates three (GIP + GLP-1 + glucagon). Phase II retatrutide data showed larger body composition changes, but it lacks FDA approval and Phase III results as of 2026. Semaglutide has the most extensive real-world evidence base of any incretin therapeutic.
Disclosure: This page contains affiliate links. We may earn from qualifying purchases. See our full disclosure.
| Criteria | Semaglutide | Retatrutide |
|---|---|---|
| Receptors targeted | GLP-1 only | GLP-1 + GIP + Glucagon |
| Max weight reduction | ~17% (68wk Phase III) | ~24% (48wk Phase II) |
| Glucagon pathway | No | Yes — hepatic lipid oxidation + thermogenesis |
| GIP pathway | No | Yes — glucose-dependent insulinotropic |
| FDA approval | Approved (2 brands, 2+ indications) | Phase III trials |
| Administration | Weekly subcutaneous | Weekly subcutaneous (Phase II protocol) |
| Real-world evidence | Extensive (millions of prescriptions) | Limited to clinical trial participants |
| Best for | Established GLP-1 research with proven safety | Multi-pathway / glucagon pathway research |
Semaglutide and retatrutide represent two generations of incretin-based research. Semaglutide proved that GLP-1 receptor agonism alone produces clinically meaningful metabolic effects. Retatrutide asks whether adding GIP and glucagon receptor engagement to GLP-1 signaling produces additive or synergistic effects.
The glucagon component is the most novel aspect. While glucagon has historically been associated with raising blood glucose, its role in hepatic lipid metabolism (driving fatty acid oxidation) and energy expenditure (thermogenesis) creates a metabolic lever that pure GLP-1 agonists cannot pull. Early data suggests this contributes to retatrutide's larger effect sizes.
However, semaglutide's advantage is maturity: FDA approval, Phase III safety data, post-marketing surveillance across millions of prescriptions, and established clinical protocols. For many research questions, the depth of available semaglutide data is unmatched.
For related comparisons, see tirzepatide vs semaglutide (dual vs single agonist) and tirzepatide vs retatrutide (dual vs triple agonist).
Current research deal — use code SOL
10% off semaglutide and retatrutide research compounds at Live Alpha Labs. Credit cards accepted. For research use only. We may earn from qualifying purchases.
Related comparison
Related comparison
Shop profile
Shop profile